File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Relationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study

TitleRelationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study
Authors
KeywordsAdipocyte-fatty acid binding protein
Adipokine
Cardiovascular outcome
Fenofibrate
Lipocalin-2
Issue Date2020
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/diabres
Citation
Diabetes Research and Clinical Practice, 2020, v. 169, p. article no. 108450 How to Cite?
AbstractAims: To investigate determinants of circulating levels of adipocyte-fatty acid binding protein (A-FABP) and lipocalin-2 (LCN2), their relationships with cardiovascular disease (CVD) and microvascular events, and effects of fenofibrate in type 2 diabetes (T2D). Methods: A-FABP and LCN2 were quantified in baseline plasma from 2000 T2D adults in a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial sub-study and correlates thereof determined. In a subset (n = 200) adipokines were also measured on-trial. Results: Female sex, older age, higher body mass index (BMI), HbA1c, insulin resistance index, triglycerides, plasma creatinine and homocysteine, shorter diabetes duration, and use of oral hypoglycaemic agents alone were independent determinants of higher A-FABP. Higher BMI, fibrinogen and homocysteine, Caucasian race, and lower fasting glucose, HDL-cholesterol, apolipoprotein A-II and estimated glomerular filtration rate were independent predictors of higher LCN2 levels. Baseline A-FABP and LCN2 levels were associated with multiple new CVD and microvascular events over 5-years, though significance was lost after risk factor adjustment. Fenofibrate increased A-FABP but did not change LCN2 levels. Conclusions: Baseline plasma A-FABP and LCN2 levels were associated with concurrent CVD risk factors, and on-trial chronic complications, likely mediated via traditional risk factors. Fenofibrate increased A-FABP modestly but did not affect LCN2 levels. Clinical Trial Registration: ISRCTN 64783481.
Persistent Identifierhttp://hdl.handle.net/10722/305394
ISSN
2023 Impact Factor: 6.1
2023 SCImago Journal Rankings: 1.340
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorOng, KL-
dc.contributor.authorWu, L-
dc.contributor.authorJanuszewski, AS-
dc.contributor.authorO'Connell, RL-
dc.contributor.authorXu, A-
dc.contributor.authorRye, KA-
dc.contributor.authorMa, RCW-
dc.contributor.authorLi, H-
dc.contributor.authorJenkins, AJ-
dc.contributor.authorJia, W-
dc.contributor.authorKeech, AC-
dc.date.accessioned2021-10-20T10:08:47Z-
dc.date.available2021-10-20T10:08:47Z-
dc.date.issued2020-
dc.identifier.citationDiabetes Research and Clinical Practice, 2020, v. 169, p. article no. 108450-
dc.identifier.issn0168-8227-
dc.identifier.urihttp://hdl.handle.net/10722/305394-
dc.description.abstractAims: To investigate determinants of circulating levels of adipocyte-fatty acid binding protein (A-FABP) and lipocalin-2 (LCN2), their relationships with cardiovascular disease (CVD) and microvascular events, and effects of fenofibrate in type 2 diabetes (T2D). Methods: A-FABP and LCN2 were quantified in baseline plasma from 2000 T2D adults in a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial sub-study and correlates thereof determined. In a subset (n = 200) adipokines were also measured on-trial. Results: Female sex, older age, higher body mass index (BMI), HbA1c, insulin resistance index, triglycerides, plasma creatinine and homocysteine, shorter diabetes duration, and use of oral hypoglycaemic agents alone were independent determinants of higher A-FABP. Higher BMI, fibrinogen and homocysteine, Caucasian race, and lower fasting glucose, HDL-cholesterol, apolipoprotein A-II and estimated glomerular filtration rate were independent predictors of higher LCN2 levels. Baseline A-FABP and LCN2 levels were associated with multiple new CVD and microvascular events over 5-years, though significance was lost after risk factor adjustment. Fenofibrate increased A-FABP but did not change LCN2 levels. Conclusions: Baseline plasma A-FABP and LCN2 levels were associated with concurrent CVD risk factors, and on-trial chronic complications, likely mediated via traditional risk factors. Fenofibrate increased A-FABP modestly but did not affect LCN2 levels. Clinical Trial Registration: ISRCTN 64783481.-
dc.languageeng-
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/diabres-
dc.relation.ispartofDiabetes Research and Clinical Practice-
dc.subjectAdipocyte-fatty acid binding protein-
dc.subjectAdipokine-
dc.subjectCardiovascular outcome-
dc.subjectFenofibrate-
dc.subjectLipocalin-2-
dc.titleRelationships of adipocyte-fatty acid binding protein and lipocalin 2 with risk factors and chronic complications in type 2 diabetes and effects of fenofibrate: A fenofibrate Intervention and event lowering in diabetes sub-study-
dc.typeArticle-
dc.identifier.emailXu, A: amxu@hkucc.hku.hk-
dc.identifier.authorityXu, A=rp00485-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.diabres.2020.108450-
dc.identifier.pmid32949655-
dc.identifier.scopuseid_2-s2.0-85091666830-
dc.identifier.hkuros328025-
dc.identifier.volume169-
dc.identifier.spagearticle no. 108450-
dc.identifier.epagearticle no. 108450-
dc.identifier.isiWOS:000598123600004-
dc.publisher.placeIreland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats